Forward P/S Multiple: Establishment Labs Holdings Inc. (ESTA)
Geopolitical strife is disrupting silicone supplies and restricting implant exports, a trend reflected in the forward P/S, where the 7.80 mark serves as the current indicator. However, stringent FDA requirements and patents provide a powerful moat for the business. Growing interest in plastic surgery across Asia and the US is driving further sales scaling for Establishment Labs (ESTA).
Summary analytical data breakdowns for Establishment Labs Inc (ESTA)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Establishment Labs|ESTA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Establishment Labs|ESTA - Company Aggregate Debts|Debt to Book Capitalization Ratio Establishment Labs Inc|ESTA - Company Long-Term Debt|Company Current Liabilities Establishment Labs|Quick Ratio establishmentlabs.com
- financial results and valuation multiples details:
ESTA - Company Net Income|Expected Profit Establishment Labs|ESTA - Market Cap to Net Income Ratio|Projected Price to Earnings Motiva|ESTA - PEG Multiple|EV/EBITDA Multiple Establishment Labs Inc|ESTA - Operating income before deduction of amortization|Earnings per share for the last twelve months Establishment Labs|ESTA - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months establishmentlabs.com|ESTA - Net earnings per share growth this year|Earnings growth forecast for next year Establishment Labs
- sales and revenue indicators:
Fundamental company analysis:ESTA (Establishment Labs Holdings Inc.)
The forward P/S ratio determines the market value of a business relative to expected sales volume, revealing the extent of an asset's overvaluation. Investors utilize this multiple to compare current market capitalization with revenue expansion rates. Analyzing the forward P/S multiple allows for the identification of entry points, preventing the purchase of overheated securities. For Establishment Labs (ESTA), this indicator reflects the market premium for technological leadership in the premium implants segment with digital tracking.
Who Establishment Labs competes with
Price-to-Projected Revenue Ratio Boston Scientific Corporation BSX|EW - Forward Price-to-Revenue Multiple|ResMed Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Insulet Inc.|ZBH: Forward P/S Multiple|Market Cap to Projected Revenue COO|ALGN (Align Technology) - Forward P/S Multiple|Globus Medical Inc (GMED) - Market Cap to Expected Sales Ratio|Forward P/S Multiple TMDX|Forward Price-to-Revenue Multiple Alphatec Corp ATEC|Forward P/S Multiple AORT (Artivion, Inc.)|Forward P/S Multiple enovis.com ENOV|IART - Price-to-Projected Revenue Ratio|BBNX: Price-to-Projected Revenue Ratio|IRMD (Iradimed) - Forward Price-to-Revenue Multiple|Embecta Health - Forward Price to Sales|TNDM (Tandem Diabetes Care) - Forward P/S Multiple|Market Cap to Future Revenue Ratio axogeninc.com AXGN|Price-to-Projected Revenue Ratio SI-BONE (SIBN)|Orthofix Medical (OFIX) - Projected Price to Revenue|Bioventus Corp - Forward Price-to-Revenue Multiple|Forward P/S Multiple OrthoPediatrics Corp KIDS|Treace Medical Concepts - Forward P/S Multiple|Market Cap to Expected Sales Ratio blade.com SRTA|Carlsmed (CARL) - Price-to-Projected Revenue Ratio|Future Price to Revenue RXST (RxSight Inc)|Price-to-Projected Revenue Ratio ClearPoint Neuro Inc.|Forward Price-to-Revenue Multiple Stereotaxis Corporation (STXS)|Forward P/S Multiple STIM|SGHT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Orchestra BioMed, Inc. OBIO|ANIK: Market Cap to Projected Revenue|NSPR: Forward Price-to-Revenue Multiple|Jin Medical International - Price to Expected Revenue Ratio|VANI: Forward P/S Multiple|Market Cap to Future Revenue Ratio Xtant Medical (XTNT)|Price-to-Projected Revenue Ratio NeuroOne Medical Technologies Corporation|Modular Med (MODD) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MYO (Myomo, Inc)|Price to Expected Revenue Ratio COCH|Forward P/S Multiple VVOS (Vivos Therapeutics)|Forward P/S Multiple envveno.com NVNO|SINTX Technologies - Forward P/S Multiple|TNON: Price-to-Projected Revenue Ratio|ReWalk Robotics Ltd (LFWD) - Price-to-Projected Revenue Ratio|AMIX (Autonomix Medical) - Price-to-Projected Revenue Ratio|IVF (INVO Fertility Inc) - Forward P/S Multiple|bonebiologics.com (BBLG) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Axonics (AXNX)|Market Cap to Expected Sales Ratio BIOLASE Inc.|Forward P/S Multiple DYNT (Dynatronics)|Forward Price to Sales FNA|INVO - Price-to-Projected Revenue Ratio
